Amneal Pharmaceuticals (AMRX) Misses Q1 EPS by 1c; Offers FY22 Guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/30/2026

1. INTC
2. AMZN
3. COIN
4. PINS
5. RDDT
6. FSLR
7. FND
8. GILD
9. SNDK
10. RBLX

Go back to Amneal Pharmaceuticals (AMRX) Misses Q1 EPS by 1c; Offers FY22 Guidance

Amneal Reports First Quarter 2022 Financial Results

May 4, 2022 6:00 AM EDT

Q1 2022 Net Revenue of $498 million; GAAP Net Loss of $2 million; Diluted Loss per Share of $(0.01)

Adjusted EBITDA (1) of $100 million includes $5 million of R&D milestone expense; Adjusted Diluted EPS (1) of $0.12

Maintaining 2022 Full Year Outlook

BRIDGEWATER, N.J.--(BUSINESS WIRE)-- Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (Amneal or the Company) announced its results today for the first quarter ended March 31, 2022.

We are very pleased with our first quarter results and the progress we have made to advance our... More